Prior Aspirin Use and Outcomes in Acute Coronary Syndromes

被引:38
作者
Rich, Jonathan D. [3 ]
Cannon, Christopher P. [1 ,2 ]
Murphy, Sabina A. [1 ,2 ]
Qin, Jie [1 ,2 ]
Giugliano, Robert P. [1 ,2 ]
Braunwald, Eugene [1 ,2 ]
机构
[1] Brigham & Womens Hosp, TIMI Study Grp, Div Cardiovasc, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Univ Chicago, Dept Med, Cardiol Sect, Chicago, IL 60637 USA
关键词
acute coronary syndromes; aspirin; myocardial infarction; prognosis; risk factors; ACUTE MYOCARDIAL-INFARCTION; TISSUE-PLASMINOGEN-ACTIVATOR; TIMI RISK SCORE; UNSTABLE ANGINA; UNFRACTIONATED HEPARIN; THERAPY; THROMBOLYSIS; CLOPIDOGREL; ENOXAPARIN; TENECTEPLASE;
D O I
10.1016/j.jacc.2010.06.028
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The purpose of this study was to determine whether patients taking aspirin before an acute coronary syndrome (ACS) are at higher risk of recurrent events or mortality. Background Controversy exists whether prior aspirin use is an independent predictor of worse outcomes in patients who experience an ACS. Methods We evaluated 66,443 ACS patients from a merged database of previous Thrombolysis in Myocardial Infarction trials. We evaluated the differences in ACS type, total mortality, and the composite end point of death, myocardial infarction (MI), recurrent ischemia, or stroke between prior aspirin and nonprior aspirin users. We used multivariate analysis to control for differences in baseline characteristics. Results Prior aspirin users (n = 17,839) were older (63 years vs. 59 years) and had more coronary risk factors and evidence of coronary artery disease (MI, angina, prior intervention) than nonprior aspirin users (n = 48,604) (all p < 0.0001). Prior aspirin use was associated with less severe types of ACS at presentation (e.g., unstable angina > non-ST-segment elevation MI > ST-segment elevation MI) than their nonaspirin user counterparts (p < 0.0001). After multivariate analysis, there was no difference in total mortality between prior aspirin users and nonaspirin users at day 30 (odds ratio [OR]: 1.01; 95% confidence interval [CI]: 0.90 to 1.13) or by the last follow-up visit (mean 328 days) (hazard ratio: 1.03; 95% CI: 0.95 to 1.11). Prior aspirin use was modestly associated with recurrent MI (OR: 1.26; 95% CI: 1.12 to 1.43) and the composite end point (OR: 1.16; 95% CI: 1.08 to 1.24). Conclusions Prior aspirin use was associated with more comorbidities and coronary disease and a higher risk of recurrent MI, but not mortality. As such, it should best be considered a marker of a patient population at high risk for recurrent adverse events after ACS. (J Am Coll Cardiol 2010;56:1376-85) (C) 2010 by the American College of Cardiology Foundation
引用
收藏
页码:1376 / 1385
页数:10
相关论文
共 42 条
[1]   Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes [J].
Alexander, JH ;
Harrington, RA ;
Tuttle, RH ;
Berdan, LG ;
Lincoff, AM ;
Deckers, JW ;
Simoons, ML ;
Guerci, A ;
Hochman, JS ;
Wilcox, RG ;
Kitt, MM ;
Eisenberg, PR ;
Califf, RM ;
Topol, EJ ;
Karsh, K ;
Ruzyllo, W ;
Stepinska, J ;
Widimsky, P ;
Boland, JB ;
Armstrong, PW .
AMERICAN JOURNAL OF CARDIOLOGY, 1999, 83 (08) :1147-1151
[2]   COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].
ALTMAN, R ;
CARRERAS, L ;
DIAZ, R ;
FIGUEROA, E ;
PAOLASSO, E ;
PARODI, JC ;
CADE, JF ;
DONNAN, G ;
EADIE, MJ ;
GAVAGHAN, TP ;
OSULLIVAN, EF ;
PARKIN, D ;
RENNY, JTG ;
SILAGY, C ;
VINAZZER, H ;
ZEKERT, F ;
ADRIAENSEN, H ;
BERTRANDHARDY, JM ;
BRAN, M ;
DAVID, JL ;
DRICOT, J ;
LAVENNEPARDONGE, E ;
LIMET, R ;
LOWENTHAL, A ;
MORIAU, M ;
SCHAPIRA, S ;
SMETS, P ;
SYMOENS, J ;
VERHAEGHE, R ;
VERSTRAETE, M ;
ATALLAH, A ;
BARNETT, H ;
BATISTA, R ;
BLAKELY, J ;
CAIRNS, JA ;
COTE, R ;
CROUCH, J ;
EVANS, G ;
FINDLAY, JM ;
GENT, M ;
LANGLOIS, Y ;
LECLERC, J ;
NORRIS, J ;
PINEO, GF ;
POWERS, PJ ;
ROBERTS, R ;
SCHWARTZ, L ;
SICURELLA, J ;
TAYLOR, W ;
THEROUX, P .
BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100
[3]  
[Anonymous], 1994, Circulation, V89, P1545
[4]  
[Anonymous], 1988, LANCET, V2, P349
[5]   The TIMI risk score for unstable angina/non-ST elevation MI - A method for prognostication and therapeutic decision making [J].
Antman, EM ;
Cohen, M ;
Bernink, PJLM ;
McCabe, CH ;
Horacek, T ;
Papuchis, G ;
Mautner, B ;
Corbalan, R ;
Radley, D ;
Braunwald, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (07) :835-842
[6]   Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction [J].
Antman, EM ;
Morrow, DA ;
McCabe, CH ;
Murphy, SA ;
Ruda, M ;
Sadowski, Z ;
Budaj, A ;
López-Sendón, JL ;
Guneri, S ;
Jiang, F ;
White, HD ;
Fox, KAA ;
Braunwald, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (14) :1477-1488
[7]   Abciximab facilitates the rate and extent of thrombolysis - Results of the thrombolysis in myocardial infarction (TIMI) 14 trial [J].
Antman, EM ;
Giugliano, RP ;
Gibson, CM ;
McCabe, CH ;
Coussement, P ;
Kleiman, NS ;
Vahanian, A ;
Adgey, AAJ ;
Menown, I ;
Rupprecht, HJ ;
Van der Wieken, R ;
Ducas, J ;
Scherer, J ;
Anderson, K ;
Van de Werf, F ;
Braunwald, E .
CIRCULATION, 1999, 99 (21) :2720-2732
[8]   Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction - Results of the ENTIRE-thrombolysis in myocardial infarction (TIMI) 23 trial [J].
Antman, EM ;
Louwerenburg, HW ;
Baars, HF ;
Wesdorp, JCL ;
Hamer, B ;
Bassand, JP ;
Bigonzi, F ;
Pisapia, G ;
Gibson, CM ;
Heidbuchel, H ;
Braunwald, E ;
Van de Werf, F .
CIRCULATION, 2002, 105 (14) :1642-1649
[9]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[10]   Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin - A randomized controlled trial [J].
Blazing, MA ;
de Lemos, JA ;
White, HD ;
Fox, KAA ;
Verheugt, FWA ;
Ardissino, D ;
DiBattiste, PM ;
Palmisano, J ;
Bilheimer, DW ;
Snapinn, SA ;
Ramsey, KE ;
Gardner, LH ;
Hasselblad, V ;
Pfeffer, MA ;
Lewis, EF ;
Braunwald, E ;
Califf, RA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (01) :55-64